FLUENZ

PreclinicalSmall molecule

IImperial College London

FLUENZ is one of 17 small molecule programs targeting Influenza. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 9

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

1 10

Fluvirin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

N/AActive, not recruiting

Influenza

NCT01866540

Clinical

Trials by Indication[1]

Influenza3 trials

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

Recruiting·IImperial College London·N/A·NCT06620185·36 enrolled

Immune Response To Intranasal Influenza Vaccination

Active, not recruiting·UUniversity of Bergen·N/A·NCT01866540·300 enrolled

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

Completed·PPublic Health England·Phase 4·NCT02143882·300 enrolled

Immune Response1 trial

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response

Completed·RRadboud University Medical Center·N/A·NCT02642237·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FLUENZ. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FLUENZ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FLUENZ. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imperial College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IImperial College London

FLUENZ

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Influenza3 trials

Immune Response1 trial

References

Drug Info

Quick Facts

Related News